faculty photo

Ian A. Blair, Ph.D.

A.N. Richards Professor of Pharmacology
Investigator, Abramson Cancer Center, University of Pennsylvania School of Medicine
Member, Institute for Medicine and Engineering, University of Pennsylvania School of Medicine
Investigator, Genomics Institute, University of Pennsylvania School of Medicine
Vice Chair, Department of Pharmacology, University of Pennsylvania School of Medicine
Director, Program in Systems Biology, Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine
Member, Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine
Director, Translational Bioanalytical Core,Center of Excellence in Environmental Toxicology
Director, Penn Superfund Research and Training Program
Department: Pharmacology

Contact information
854 Biomedical Research Building II/III
University of Pennsylvania School of Medicine
Center for Cancer Pharmacology
421 Curie Boulevard
Philadelphia, PA 19104-6160
Office: (215) 573-9880
Fax: (215) 573-9889
Graduate Group Affiliations
Education:

Cambridge Grammar School for Boys, United Kingdom , 1960.

Prince of Wales School, Nairobi, Kenya, 1963.
B.Sc. ((Special) Chemistry, ARCS)
Imperial College of Science and Technology, University of London, United Kingdom, 1968.
Ph.D.
Imperial College of Science and Technology, University of London, United Kingdom, 1971.
MRSC (Organic Chemistry)
Adelaide University, Australia, 1972.
ARACI
Australian National University, 1977.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Establish the use of high-resolution mass spectrometry and molecular biology as tools for conducting sophisticated proteomics, DNA-adductomics, metabolomics, and lipidomics research with a particular emphasis on discovering biomarkers for the early detection of cancer and biomarkers of response in rare diseases

1. Early detection biomarkers of asbestos exposure, mesothelioma, and non-small lung cancer,

Amyloid β-peptides and high-mobility group box 1 (HMGB1) a non-histone chromosomal protein are the two most intensively studied endogenous cellular danger signals known as danger-associated molecular pattern (DAMP) molecules. DAMPs together with pathogen-associated molecular patterns alert the innate immune system by activating signal transduction pathways through binding to pattern recognition receptors (PRRs). PRRs include the receptor for advanced glycation end products (RAGE), toll-like receptors (TLRs), chemokine (C-X-C motif) receptor (CXCR), and T cell immunoglobulin mucin (TIM). Binding to PRRs induces pro-inflammatory cascades, which trigger the release of cytokines. PRRs are expressed by cells of the innate immune system such as macrophages, leukocytes and dendritic cells. They are also expressed on the surface of vascular cells, fibroblasts and epithelial cells. We have recently demonstrated that HMGB1 is secreted when blood is allowed to clot. Numerous studies have reported that HMGB1 is secreted in o the circulation by cancer patients. However, many of these studies are flawed because they used serum instead of plasma. Furthermore there are 29 reported sites of acetylation on HMGB1 so it is essential that the methodology is available to quantify each of the individual proteoforms. We are currently developing an approach for the analysis of HMGB1 proteoforms in plasma samples from patients with mesothelioma and non-small cell lung cancer as well as subjects who had a heavy exposure to asbestos. We are also quantifying lipid hydroperoxide-mediated DNA damage in lymphocytes from the same population in order to further understand the etiology of the disease. Finally, metabolomics and lipidomics studies are being conducted in order to discover additional biomarkers.

2. Biomarkers of therapeutic response in rare diseases.

There are > 40 rare genetic diseases that result from aberrant protein expression including, Duchene’s muscular dystrophy (DMD), spinocerebellar ataxia 1 (SCA-1), and Friedreich’s ataxia (FA). Current approaches to developing therapies for these rare diseases primarily involve increasing expression of the normal protein. The necessity for monitoring protein levels was highlighted recently during the US Food and Drug Administration (FDA) fast-track approval process for the drug eteplirsen (Exondys 51) to treat DMD. The lack of a rigorously validated method to assess up-regulation of dystrophin levels in DMD patients made it difficult to show a therapeutic response. FA is characterized by slowly progressive ataxia and hypertrophic cardiomyopathy. Lifespan is significantly reduced in FA with an average of death of 37-years, most commonly from cardiac-related pathologies. There are no approved treatments for FA, although numerous experimental approaches are being tested, which primarily involve up-regulation of frataxin protein. We have developed a strategy to monitor improvements in mitochondrial metabolism using FA platelets. We are now developing more direct measure of frataxin expression. This will also provide an approach to monitor new therapies that are being developed for rare genetic diseases of aberrant protein expression such as DMD24 and SCA-1.

Selected Publications

Wang Q, Guo L, Strawser CJ, Hauser LA, Hwang WT, Snyder NW, Lynch DR, Mesaros C, Blair IA : Low apolipoprotein A-I levels in Friedreich's ataxia and in frataxin-deficient cells: Implications for therapy. PLoS One 13(2): e0192779, Feb 2018.

Mazaleuskaya LL, Salamatipour A, Sarantopoulou D, Weng L, FitzGerald GA, Blair IA, Mesaros C. : Analysis of hydroxyeicosatetraenoic acids (HETEs) in human whole blood by chiral ultrahigh performance liquid chromatgraphy (UHPLC)-electron capture atmospheric pressure chemical ionization/high resolution mass spectrometry (ECAPCI/HRMS). J Lipid Res. 59(3): 564-575, Mar 2018.

Guo L, Wang Q, Weng L, Hauser LA, Strawser CJ, Rocha AG, Dancis A, Mesaros C, Lynch DR, Blair IA. : Liquid Chromatography-High Resolution Mass Spectrometry Analysis of Platelet Frataxin as a Protein Biomarker for the Rare Disease Friedreich's Ataxia. Anal Chem. 90(3): 2216-2223, Feb 2018.

Guo L, Shestov AA, Worth AJ, Nath K, Nelson DS, Leeper DB, Glickson JD, Blair IA.: Inhibition of Mitochondrial Complex II by the Anticancer Agent Lonidamine. J Biol Chem. 291(1): 42-57, Jan 2016.

Mesaros C, Blair IA.: Mass spectrometry-based approaches to targeted quantitative proteomics in cardiovascular disease. Clin Proteom 13:20. eCollection, Oct 2016

Worth AJ, Basu SS, Deutsch EC, Hwang WT, Snyder NW, Lynch DR, Blair IA: Stable isotopes and LC-MS for monitoring metabolic disturbances in Friedreich's ataxia platelets. Bioanalysis 7(15): 1843-55, 2015.

Basu SS, Mesaros C, Gelhaus SL, Blair IA: Stable isotope labeling by essential nutrients in cell culture for preparation of labeled coenzyme A and its thioesters. Analytical chemistry 83(4): 1363-9, Feb 2011.

Blair IA: Analysis of estrogens in serum and plasma from postmenopausal women: Past present, and future. Steroids 75(4-5 ): 297-306, Jan 28 2010.

Yu KH, Barry CG, Austin D, Busch CM, Sangar V, Rustgi AK, Blair IA: Stable isotope dilution multidimensional liquid chromatography-tandem mass spectrometry for pancreatic cancer serum biomarker discovery. J Proteome Res 8(3): 1565–1576, 2009.

Mesaros C, Lee SH, Blair IA: Targeted quantitative analysis of eicosanoid lipids in biological samples using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 877(26): 2736-2745, 2009.

Blair IA: DNA-adducts with lipid peroxidation products. J Biol Chem 283(23): 15545-9, 2008.

back to top
Last updated: 04/26/2018
The Trustees of the University of Pennsylvania